Janssen expands partnership with ConcertAI to improve trial diversity
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Janssen expands partnership with ConcertAI to improve trial diversity

25 Aug 2021 (Last Updated August 25th, 2021 15:44)

ConcertAI is collaborating with Janssen and its data science team to facilitate quicker clinical strategies and study designs.

Janssen Research & Development has expanded its multi-year partnership with AI-based precision oncology solutions developer ConcertAI across various disease programmes.

As part of the collaboration, ConcertAI leverages AI and data science expertise with ‘high depth’ real-world clinical data.

The company is working with Janssen and its Research & Development Data Science team on insights that enable clinical strategies and study designs faster than traditional methods.

With the latest expansion, the companies will further widen access to trials at new sites and improve trial diversity.

ConcertAI CEO Jeff Elton said: “ConcertAI’s novel working model integrates the largest and deepest clinical and genomic data, enterprise AI, and will partner with Janssen and the world’s leading data scientists and research scientists to generate evidence in support of critical disease insights and regulatory decisions.

“We are proud to collaborate with Janssen to drive effective medicines for the benefit of patients with the highest unmet medical needs.”

Citing a published report, ConcertAI noted that 40% of people in the US are considered racial or ethnic minority members but only a smaller percentage of patients enrolled in trials are minorities.

Janssen aims to boost trial diversity to ensure representation of the patients who are most impacted by the disease, identifying that access to patients is limited if they are not.

ConcertAI Scientific Partnerships & Customer Success vice-president Warren Whyte said that the company provides extensive and representative oncology, haematology and urology real-world data that is obtained independently.

Whyte added: “That data, and our network of leading experts and advocates for healthcare equity, is moving us forward with leaders like those at Janssen.”

The expanded partnership with Janssen will facilitate ConcertAI to bolster the data sources used and enter earlier into disease states.

ConcertAI intends to enhance patient access to new therapies via trials and higher evidence generation to support the new standards of care.